Literature DB >> 22781680

T-cell therapy at the threshold.

Carl June1, Steven A Rosenberg, Michel Sadelain, Jeffrey S Weber.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22781680      PMCID： PMC6332500          DOI： 10.1038/nbt.2305

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  3 in total

1.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

Authors:  Paul F Robbins; Richard A Morgan; Steven A Feldman; James C Yang; Richard M Sherry; Mark E Dudley; John R Wunderlich; Azam V Nahvi; Lee J Helman; Crystal L Mackall; Udai S Kammula; Marybeth S Hughes; Nicholas P Restifo; Mark Raffeld; Chyi-Chia Richard Lee; Catherine L Levy; Yong F Li; Mona El-Gamil; Susan L Schwarz; Carolyn Laurencot; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

2.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

3.  Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.

Authors:  Daniel Hollyman; Jolanta Stefanski; Mark Przybylowski; Shirley Bartido; Oriana Borquez-Ojeda; Clare Taylor; Raymond Yeh; Vanessa Capacio; Malgorzata Olszewska; James Hosey; Michel Sadelain; Renier J Brentjens; Isabelle Rivière
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456
  3 in total
  29 in total

1.  Immune Mechanisms Are Major Players in Cancer.

Authors:  Karl Erik Hellstrom; Ingegerd Hellstrom
Journal:  Clin Cancer Res       Date:  2015-04-22       Impact factor: 12.531

Review 2.  Building better monoclonal antibody-based therapeutics.

Authors:  George J Weiner
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

3.  Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells.

Authors:  Bonnie Huang; Wuhbet D Abraham; Yiran Zheng; Sandra C Bustamante López; Samantha S Luo; Darrell J Irvine
Journal:  Sci Transl Med       Date:  2015-06-10       Impact factor: 17.956

Review 4.  Genetically modified T-cell therapy for osteosarcoma.

Authors:  Christopher DeRenzo; Stephen Gottschalk
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

5.  Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells.

Authors:  Kota Iwahori; Sunitha Kakarla; Mireya P Velasquez; Feng Yu; Zongzhen Yi; Claudia Gerken; Xiao-Tong Song; Stephen Gottschalk
Journal:  Mol Ther       Date:  2014-08-21       Impact factor: 11.454

6.  CAR-T field booms as next-generation platforms attract big players.

Authors:  Chris Morrison
Journal:  Nat Biotechnol       Date:  2015-06       Impact factor: 54.908

Review 7.  Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?

Authors:  Christopher A Klebanoff; Luca Gattinoni; Nicholas P Restifo
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

8.  Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.

Authors:  Cor Hj Lamers; Stefan Sleijfer; Sabine van Steenbergen; Pascal van Elzakker; Brigitte van Krimpen; Corrien Groot; Arnold Vulto; Michael den Bakker; Egbert Oosterwijk; Reno Debets; Jan W Gratama
Journal:  Mol Ther       Date:  2013-02-19       Impact factor: 11.454

9.  Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.

Authors:  Stephen R Goding; Kyle A Wilson; Ying Xie; Kristina M Harris; Aparna Baxi; Akgul Akpinarli; Amy Fulton; Koji Tamada; Scott E Strome; Paul Andrew Antony
Journal:  J Immunol       Date:  2013-03-27       Impact factor: 5.422

10.  Koch Institute Symposium on Cancer Immunology and Immunotherapy.

Authors:  Adam Drake; Nikhil S Joshi; Gregory L Szeto; Eric Zhu; Herman N Eisen; Darrell J Irvine
Journal:  Cancer Immunol Res       Date:  2013-10       Impact factor: 11.151
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.